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NEOADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED PRE-
MENOPAUSAL BREAST CANCER IN NIGERIAN WOMEN: EARLY
EXPERIENCE







Breast Oncology Unit, Department of Surgery, Nnamdi Azikiwe University Teaching Hospital, Nnewi,
Nigeria.
Breast cancer, the commonest female malignancy in Nigeria presents late, with bulky loco-
regional masses and predominantly in a pre and peri-menopausal setting. Treatment when feasible has been
with mutilative surgery with a poor patient acceptance rate. Chemotherapy which is widely used in adjuvant
and metastatic settings has recently been indicated in the neo-adjuvant setting.
Locally-advanced female breast cancer patients [AJCC Stages IIIA, IIIB, IIIC], seen in the breast
clinic from July, 2006 to March 2007 were recruited into the study after informed consent. Patients received
doxorubicin, 5-fluoro-uracil and cyclophsphamide by intravenous bolus or infusional injection on a three
weekly regimen as day cases. The dominant lesion was assessed by calipers at each visit. Therapeutic clinical
responses were assessed as none; partial, complete.
During the period 32 women (33 breast cancers) were seen and recruited. The numbers steadily
declined over time and only 28 completed the treatment modality. Mean pre-chemotherapy tumour size was
13.5cm which declined to 7 cm at the 5 . One patient (3.6%) exhibited complete clinical response, 25 (89%),
partial response and 2 had no response. No serious toxicities were noted.
Neo-adjuvant chemotherapy using anthracycline based regimens is efficacious and safe in
reducing tumour bulk in locally advanced breast cancers. The use should be encouraged to make bulky tumours
operable.
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INTRODUCTION
Breast cancer is the commonest female malignancy
in parts of Nigeria as it is in most other parts of
world . Breast cancer in Nigeria presents late, with
bulky loco-regional masses and predominantly in a
pre and peri-menopausal setting . Treatment when
feasible has been with mutilative surgery [total
mastectomy, toilet mastectomy]. Whereas an
increasingly higher proportion of patients in the
developed world now receive conservative surgery
due to earlier presentation and patient education the
number of patients receiving such treatment in
Nigeria is negligible. The use of neo-adjuvant
therapy [hormonal in postmenopausal patients and
cancer chemotherapeutic agents in pre-menopausal
patients] have achieved significant down-staging in






Because of the relative younger age of our patients,





Our previous experiences with cancer chemotherapy
in the adjuvant and palliative settings have attested to
its acceptability and low rate of side effects . We
decided to initiate a study of neo-adjuvant
chemotherapy in our pre-menopausal patients with
locally advanced breast cancer to see whether
significant down-staging will occur.
Locally-advanced
female breast cancer patients [AJCC Stages IIIA,
IIIB, IIIC] attending the Breast oncology clinics of
Nnamdi Azikiwe University Teaching Hospital,
Nnewi from July, 2006 to March 2007 were recruited
into the study after informed consent. Patients' bio-
data, height, weight, menopausal status and blood
indices were collected. Primary cancer sites in the
breast were measured with calipers at presentation
and on subsequent visits. After histological
confirmation of invasive ductal breast cancer from
corecut biopsies patients were given doxorubicin
[50mg/m ], 5-fluoro-uracil [500mg/m ] and
cyclophsphamide [600mg/m ] by intravenous bolus






Results from this study support those of other
workers that neo-adjuvant chemotherapy is
beneficial to patients with locally advanced breast
cancer. Overall, the complete clinical response rate is
lower than in other published figures probably due to
higher volume primary masses, higher nodal status
and other unidentified factors which Fernandez-
Sanchez and colleagues and Prisack et al have
suggested might cause lower responses. In addition
to down-staging the lesions for operability other
reported benefits include breast conservation and
assessment of in vivo response to further drug
treatment .
Clinical (caliper) measurement of tumour bulk,
though acceptable in low technology societies has
been supplanted by use of imaging modalities for
tumour assessment. These modalities include
ultrasongraphy, MRM, PET and mammography .
Caliper measurement is believed to give false higher
figures , probably because of inclusion of skin and
subcutaneous tissue in the measurement, and also
possible inclusion of peri-tumoral fibrosis with
induration.
The side-effect profiles in this study and in similar
studies are acceptable even in absence of dedicated
medical oncologist in most hospitals.
Addition of taxanes to anthracycline containing
regimens have been reported to give better results as
is the use of targeted immunotherapies like
trastuzumab . Whereas hormonal manipulations
using tamoxifen or aromatase inhibitors in estrogen
receptor - positive and estrogen receptor unknown
post-menopausal patients have been associated with
better response and less toxicity, breast cancer still
remains a mainly pre-menopausal disease in many
parts of the developing world and the use of hormone
therapy in this group is still controversial. Hopefully
availability of more radiotherapy services and
extension of neo-adjuvant therapy to AJCC stage I








day cases. On each visit the dominant cancer lesion
was measured in two planes with a caliper,
haematological indices were assessed and evidence
of drug toxicity was sought. Therapeutic clinical
responses were assessed as none; if the tumour
progressed or showed non-significant [less than
20%] reduction in largest diameter at last
assessment; partial, if there was significant [greater
than 20%] reduction in largest diameter but mass still
palpable; and complete, if no residual tumour was
palpable. Facilities for estrogen or other receptors
and histiochemistry were not available during the
study.
During the period 32 women (33 breast
cancers) were seen and recruited. Five women were
not seen again after the first dose. Of the 28 evaluable
breast cancers (27 women) the numbers steadily
declined to 13(46%) remaining at the 5 week.
Reasons for dropout were mainly financial as the
hospital operated a fee for service.
Mean patient age was 42.8 years [Range 30-49].
Twenty-five women were pre-menopausal and 2
within 5 years of menopause. Twenty percent had no
formal education, 15% tertiary education while the
rest had combination of primary and secondary
education. The mean parity was 3.92 [Range 0-8].
Nine cancers (25%) were IIIA; 16 (57%), IIIB and 3
(18%) IIIC. The mean pre-chemotherapy tumour
size was 13.5cm [Range 7-35cm]. This declined
steadily to mean of 7 cm at the 5 visit. One patient
(3.6%) exhibited complete clinical response, 25
(89%), partial response and 2 had no response. Pre-
chemotherapy size of tumour was not related to
response rates. Haematologic or other toxicities were
minimal, 25% had dose deferment of 1-2 weeks due






























acceptance of breast conservation in the 3 world.
This might mark a turning point in the fight against
the disease where a vicious cycle of ignorance, high
mortality and fear of mutilative surgery have
conspired to make patients present late to orthodox
practitioners.
Neo-adjuvant chemotherapy using anthracycline
based regimens is efficacious in reducing tumour
bulk in locally advanced breast cancers. Since 3
world breast cancers still present late addition of neo-
adjuvant chemotherapy in the treatment guidelines
might improve operability and reduce gloom
associated with disease.
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